Efficacy of lenvatinib in patients with advanced pancreatic (panNETs) and gastrointestinal (giNETs) grade 1/2 (G1/G2) neuroendocrine tumors: Results of the international phase II TALENT trial (GETNE 1509)
Capdevila, J.; Fazio, N.; Lopez, C.; Teule, A.; Valle, J.W.; Tafuto, S.; Custodio, A.; Reed, N.; Raderer, M.; Grande, E.; Garcia-Carbonero, R.; Jimenez Fonseca, P.; Alonso, V.; Antonuzzo, L.; Spallanzani, A.; Berruti, A.; Sevilla Garcia, I.; La Casta, A.; Hernando, J.; Ibrahim, T.
Annals of Oncology Official Journal of the European Society for Medical Oncology 29 Suppl. 8: Viii 467
2018
ISSN/ISBN: 0923-7534 PMID: 32137197 DOI: 10.1093/annonc/mdy293
Accession: 069883922
PDF emailed within 0-6 h: $19.90
Related References
Capdevila, J.; Fazio, N.; Lopez, C.; Teulé, A.; Valle, J.W.; Tafuto, S.; Custodio, A.; Reed, N.; Raderer, M.; Grande, E.; Garcia-Carbonero, R.; Jimenez-Fonseca, P.; Hernando, J.; Bongiovanni, A.; Spada, F.; Alonso, V.; Antonuzzo, L.; Spallanzani, A.; Berruti, A.; La Casta, A.; Sevilla, I.; Kump, P.; Giuffrida, D.; Merino, X.; Trejo, L.; Gajate, P.; Matos, I.; Lamarca, A.; Ibrahim, T. 2021: Lenvatinib in Patients with Advanced Grade 1/2 Pancreatic and Gastrointestinal Neuroendocrine Tumors: Results of the Phase Ii TALENT Trial (GETNE1509) Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology 39(20): 2304-2312Grande Pulido, E.; Teule, A.; Alonso-Gordoa, T.; Jiménez-Fonseca, P.; Benavent, M.; Capdevila, J.; Custodio, A.; Vera, R.; Munarriz, J.; La Casta-Muñoa, A.; Garcia-Carbonero, R. 2017: A phase Ii trial of palbociclib in metastatic grade 1/2 pancreatic neuroendocrine tumors: the PALBONET study on behalf of the Spanish Taskforce Group of Neuroendocrine Tumors (GETNE) Annals of Oncology 28: V142-V143
Grande, E.; Teulé, A.; Alonso-Gordoa, T.; Jiménez-Fonseca, P.; Benavent, M.; Capdevila, J.; Custodio, A.; Vera, R.; Munarriz, J.; La Casta, A.; Díez, J.J.é; Gajate, P.; Molina-Cerrillo, J.; Matos, I.; Cristóbal, E.M.ía.; Ruffinelli, J.é C.; Palacios, J.é; García-Carbonero, R.ío. 2020: The PALBONET Trial: a Phase Ii Study of Palbociclib in Metastatic Grade 1 and 2 Pancreatic Neuroendocrine Tumors (GETNE-1407) Oncologist 25(9): 745-E1265
Grande, E.; Rodriguez-Antona, C.; López, C.; Alonso-Gordoa, T.; Benavent, M.; Capdevila, J.; Teulé, A.; Custodio, A.; Sevilla, I.; Hernando, J.; Gajate, P.; Molina-Cerrillo, J.; Díez, J.J.é; Santos, M.ía.; Lanillos, J.; García-Carbonero, R.ío. 2021: Sunitinib and Evofosfamide (TH-302) in Systemic Treatment-Naïve Patients with Grade 1/2 Metastatic Pancreatic Neuroendocrine Tumors: the GETNE-1408 Trial Oncologist 26(11): 941-949
Yao, J.C.; Phan, A.T.; Chang, D.Z.; Wolff, R.A.; Hess, K.; Gupta, S.; Jacobs, C.; Mares, J.E.; Landgraf, A.N.; Rashid, A.; Meric-Bernstam, F. 2008: Efficacy of RAD001 (everolimus) and octreotide LAR in advanced low- to intermediate-grade neuroendocrine tumors: results of a phase Ii study Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology 26(26): 4311-4318
Pozzari, M.; Maisonneuve, P.; Spada, F.; Berruti, A.; Amoroso, V.; Cella, C.A.; Laffi, A.; Pellicori, S.; Bertani, E.; Fazio, N. 2018: Systemic therapies in patients with advanced well-differentiated pancreatic neuroendocrine tumors (PanNETs): when cytoreduction is the aim. a critical review with meta-analysis Cancer Treatment Reviews 71: 39-46
Vinik, A.; Bottomley, A.; Korytowsky, B.; Bang, Y-Jue.; Raoul, J-Luc.; Valle, J.W.; Metrakos, P.; Hörsch, D.; Mundayat, R.; Reisman, A.; Wang, Z.; Chao, R.C.; Raymond, E. 2016: Patient-Reported Outcomes and Quality of Life with Sunitinib Versus Placebo for Pancreatic Neuroendocrine Tumors: Results From an International Phase III Trial Targeted Oncology 11(6): 815-824
Lombard-Bohas, C.; Yao, J.C.; Hobday, T.; Van Cutsem, E.; Wolin, E.M.; Panneerselvam, A.; Stergiopoulos, S.; Shah, M.H.; Capdevila, J.; Pommier, R. 2015: Impact of prior chemotherapy use on the efficacy of everolimus in patients with advanced pancreatic neuroendocrine tumors: a subgroup analysis of the phase IIi RADIANT-3 trial Pancreas 44(2): 181-189
Worth, P.J.; Leal, J.; Ding, Q.; Trickey, A.; Dua, M.M.; Chatzizacharias, N.; Soonawalla, Z.; Athanasopoulos, P.; Toumpanakis, C.; Hansen, P.; Parks, R.W.; Connor, S.; Parker, K.; Koea, J.; Srinavasa, S.; Ielpo, B.; Vicente Lopez, E.; Lawrence, B.; Visser, B.C. 2020: Pancreatic grade 3 neuroendocrine tumors behave similarly to neuroendocrine carcinomas following resection: a multi-center, international appraisal of the WHO 2010 and WHO 2017 staging schema for pancreatic neuroendocrine lesions Hpb: the Official Journal of the International Hepato Pancreato Biliary Association 22(9): 1359-1367
Singhi, A.D.; Klimstra, D.S. 2018: Well-differentiated pancreatic neuroendocrine tumours (PanNETs) and poorly differentiated pancreatic neuroendocrine carcinomas (PanNECs): concepts, issues and a practical diagnostic approach to high-grade (G3) cases Histopathology 72(1): 168-177
Riesco-Martinez, M.; Capdevila, J.; Alonso, V.; Jimenez-Fonseca, P.; Teule, A.; Grande, E.; Sevilla, I.; Benavent Viñuales, M.; Alonso-Gordoa, T.; Custodio, A.; Hernando, J.; Polo, E.; Castillo Trujillo, O.; Garcia-Carbonero, R. 2021: 1098O Nivolumab plus platinum-doublet chemoTherapy as first-line Therapy in unresectable, locally advanced or metastatic G3 neuroendocrine Neoplasms (NENs) of the gastroenteropancreatic (GEP) tract or unknown (UK) origin: Preliminary results from the phase Ii NICE-NEC trial (GETNE T1913) Annals of Oncology 32: S908-S909
Yao, J.; Fazio, N.; Singh, S.; Buzzoni, R.; Carnaghi, C.; Wolin, E.; Tomasek, J.; Raderer, M.; Lahner, H.; Voi, M.; Pacaud, L.; Lincy, J.; Sachs, C.; Valle, J.; Delle Fave, G. 2015: 5Lba Everolimus in advanced nonfunctional neuroendocrine tumors (Net) of lung or gastrointestinal (Gi) origin: Efficacy and safety results from the placebo-controlled, double-blind, multicenter, Phase 3 Radiant-4 study European Journal of Cancer 51: S709-S710
Neychev, V.; Steinberg, S.M.; Cottle-Delisle, C.; Merkel, R.; Nilubol, N.; Yao, J.; Meltzer, P.; Pacak, K.; Marx, S.; Kebebew, E. 2015: Mutation-targeted therapy with sunitinib or everolimus in patients with advanced low-grade or intermediate-grade neuroendocrine tumours of the gastrointestinal tract and pancreas with or without cytoreductive surgery: protocol for a phase Ii clinical trial Bmj Open 5(5): E008248
Halperin, D.M.; Lee, J.J.; Ng, C.S.; Strosberg, J.R.; Estrella, J.S.; Dagohoy, C.G.; Dasari, A.; Yao, J.C. 2019: A Phase Ii Trial of Ziv-Aflibercept in Patients with Advanced Pancreatic Neuroendocrine Tumors Pancreas 48(3): 381-386
Cai, L.; Michelakos, T.; Deshpande, V.; Arora, K.S.; Yamada, T.; Ting, D.T.; Taylor, M.S.; Castillo, C.F.-D.; Warshaw, A.L.; Lillemoe, K.D.; Ferrone, S.; Ferrone, C.R. 2019: Role of Tumor-Associated Macrophages in the Clinical Course of Pancreatic Neuroendocrine Tumors (PanNETs) Clinical Cancer Research: An Official Journal of the American Association for Cancer Research 25(8): 2644-2655
Battistella, A.; Partelli, S.; Andreasi, V.; Marinoni, I.; Palumbo, D.; Tacelli, M.; Lena, M.S.; Muffatti, F.; Mushtaq, J.; Capurso, G.; Arcidiacono, P.G.; De Cobelli, F.; Doglioni, C.; Perren, A.; Falconi, M. 2022: Preoperative assessment of microvessel density in nonfunctioning pancreatic neuroendocrine tumors (NF-PanNETs) Surgery 172(4): 1236-1244
Capdevila, J.; Teule, A.; López, C.; García-Carbonero, R.; Benavent, M.; Custodio, A.; Cubillo, A.; Alonso, V.; Gordoa, T.A.; Carmona-Bayonas, A.; Crespo, G.; Blanco-Codesido, M.; Jimenez-Fonseca, P.; Viúdez, A.; La Casta Muñoa, A.; Sevilla, I.; Llanos, M.; Segura, A.; Hernando-Cubero, J.; Manzano, J. 2020: 1157O a multi-cohort phase Ii study of durvalumab plus tremelimumab for the treatment of patients (pts) with advanced neuroendocrine neoplasms (NENs) of gastroenteropancreatic or lung origin: the DUNE trial (GETNE 1601) Annals of Oncology 31: S770-S771
Paganelli, G.; Sansovini, M.; Ambrosetti, A.; Severi, S.; Monti, M.; Scarpi, E.; Donati, C.; Ianniello, A.; Matteucci, F.; Amadori, D. 2014: 177 Lu-Dota-octreotate radionuclide therapy of advanced gastrointestinal neuroendocrine tumors: results from a phase Ii study European Journal of Nuclear Medicine and Molecular Imaging 41(10): 1845-1851
Finkelstein, P.; Sharma, R.; Picado, O.; Gadde, R.; Stuart, H.; Ripat, C.; Livingstone, A.S.; Sleeman, D.; Merchant, N.; Yakoub, D. 2017: Pancreatic Neuroendocrine Tumors (panNETs): Analysis of Overall Survival of Nonsurgical Management Versus Surgical Resection Journal of Gastrointestinal Surgery: Official Journal of the Society for Surgery of the Alimentary Tract 21(5): 855-866
Partelli, S.; Gaujoux, S.; Boninsegna, L.; Cherif, R.; Crippa, S.; Couvelard, A.; Scarpa, A.; Ruszniewski, P.; Sauvanet, A.; Falconi, M. 2013: Pattern and clinical predictors of lymph node involvement in nonfunctioning pancreatic neuroendocrine tumors (NF-PanNETs) JAMA Surgery 148(10): 932-939